In 2019 the global platelet rich plasma market was valued at USD 211.96 million and predicted to hit around USD 715.65 million by 2030 growing at a CAGR of 11.6% during the forecast period 2021 to 2030.
Platelet rich plasma (PRP) therapy has gathered substantial attention over the last few decades, primarily owed to its latent capability in regenerative medicine such as maxillofacial and oral surgery, veterinary and sports medicine. Platelets as a key component of the PRP, comprise above 1100 diverse proteins, with plentiful post-translational alterations, ensuing in above 1500 protein-based bioactive aspects. These aspects embrace growth factors, immune system messengers, enzymes and their inhibitors and other factors which can contribute in wound healing and tissue repair.
Intensifying elderly population and mounting pervasiveness of orthopedic circumstances are certain other influences pushing the growth of platelet rich plasma marketplace. As per data published by National Center for Biotechnology Information, more than 1.4 million people are identified with fractures associated to osteoporosis each year. Furthermore, intensifying alertness related to platelet rich plasma therapy for dental treatment is projected to augment the market development.
Among different product segment analyzed in this research report, pure PRP conquered the overall market in 2020. Pure PRP reduces red neutrophils and blood cells. Neutrophils and red blood cells, white blood cell, have no therapeutic effect, and also encompass inflammatory components, which may upsurge pain post treatment. Nevertheless, leukocyte-rich fibrin is anticipated to progress at the fastest growth rate during the estimate period. Leukocyte-rich fibrin offers enhanced healing response and suggestively decreased retrieval time.
|Market Size||USD 715.65 Million by 2030|
|Growth Rate||CAGR of 11.6% From 2021 to 2030|
|Historic Data||2017 to 2020|
|Forecast Period||2021 to 2030|
|Segments Covered||Product, Origin, Application|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)|
|Companies Mentioned||Zimmer Biomet, Arthrex, Inc., Harvest Technologies Corporation, Stryker Corporation, DePuy Synthes, Inc., Cesca Therapeutics, Inc., AdiStem Ltd., Exactech Inc., ISTO Biologics, Nuo Therapeutics|
Different applications covered in the market are cosmetic surgery, orthopedic surgery, neurosurgery, general surgery and others.Among all,in 2019, orthopedics application segment led the global PRP market.Osteoarthritis is the most dominant kind of arthritis, and it affects around 31 million Americans each year. Due to increasing elderly populace, occurrence of doctor-diagnosed arthritis is projected to upsurge suggestively during prediction period.
Cosmetic surgery segment is projected to advance at rapid pace within assessment period on account of intensification in the applications of platelet-rich plasma products in hair transplant and other cosmetic applications. Platelet-rich plasma therapy is witnessing a momentous growth in its acceptance and reception for arthritis treatment as it impedes inflammation, cuts the rate of progression of osteoarthritis, motivates the formation of new cartilage, and upsurges the production of natural lubricating joint fluid. In this way, it eases painful joint friction, and also encompasses proteins that modify a patient's pain receptors and decreases pain sensation. Thus, the above-mentioned factors are anticipated to accelerate the growth of the arthritis segment.
Depending on origin, global platelet-rich plasma market has been categorized into autologous, allogeneic, and homologous platelet-rich plasma. The autologous platelet-rich plasma segment is expected to govern the global platelet-rich plasma market throughout the estimate period on account of purging of cost for the fees to be paid to blood donors and clinical scrutiny of blood-borne diseases.
Geographically, North America garnered major stake in the global platelet-rich plasma market as it is base of most significant players who are operating in the field of PRP market. North America and Europe are likely to lead the global market arena throughout the prediction period, mostly owed to the great occurrence of orthopedic disorders, upsurge in occurrence rates of rheumatology, intensification in the amount of sport wounds, and rush in acceptance of platelet-rich plasma therapy.
Asia Pacific is anticipated to record the rapid growth during upcoming years. Government bodies of emerging nations such as Mexico, India, and Brazil, are making enormous investments to create alertness concerning plasma therapy. PRP marketplace is expected to advance at a lucrative rate as it has the latent to support in delivering improved management of numerous orthopedic problems associated to wrist, elbow, shoulder, hip, back, knee, and ankle, which are on the upsurge in evolving regions.
Key Companies & Market Share Insights
Foremost companies in the global platelet-rich plasma market are engrossed on implementing collaboration and partnership tactics to augment their market stake. For example, in 2019, CollPlant, rehabilitated its special distribution contract with Arthrex for Vergenix STR, an injectable gel consists of cross-linked bioengineered recombinant human typeI collagen, rhCollagen, along with autologous platelet-rich plasma for tendinopathy treatment.
Certain prominent companies functioning in the Platelet Rich Plasma market are as follows:
Segments Covered in the Report
This research report includes complete assessment of the market with the help of extensive qualitative and quantitative insights, and projections regarding the market. This report offers breakdown of market into prospective and niche sectors. Further, this research study calculates market revenue and its growth trend at global, regional, and country from 2016 to 2030. This report includes market segmentation and its revenue estimation by classifying it on the basis of product, origin, application and region as follows:
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence client